People in the News
Life sciences investment group Abingworth Management, which holds a stake in Alnylam Pharmaceuticals, said this week that it has appointed Tim Haines as a partner.
Haines will be responsible for identifying and creating new businesses, as well as providing support for existing companies within the Abingworth portfolio, the firm said.
Haines is currently CEO of Astex Therapeutics, and will join Abingworth in September. Before Astex, he was CEO of two division of the medical technology firm Datascope. He has a BSc from Exeter University and an MBA from INSEAD.
John Rossi, a researcher at City of Hope's Beckman Research Institute, has joined the scientific advisory board of NanoViricides, the company said last week.
Rossi is currently adjunct professor of the division of biomedical sciences at the University of California, Riverside, and adjunct professor in the department of biochemistry and microbiology at Loma Linda University.
He received his PhD in microbial genetics from the University of Connecticut. He also currently sits on the SAB of Calando Pharmaceuticals, which he co-founded, and Benitec. He also is a board member at CytoGenix.
Products & Services
Ambion recently announced the launch of the Silencer CellReady siRNA libraries, a new line of pre-plated, ready-to-transfect siRNA libraries.
According to the company, pre-defined siRNA set includes three individual siRNAs per target plated in the ideal amount for use in a single RNAi screen in human cells. This initial launch will include libraries targeting human kinases and the "druggable" genome, as well as two libraries targeting commonly studied genes.
Additional details about the libraries can be found at http://www.ambion.com/catalog/CatNum.php?82xxx.